News 20.11.2020 Schlieren (Zurich), Switzerland, November 20, 2020 – Kuros Biosciences (SIX: KURN) today announced that it has won the 2020 Spine Technology Award, awarded by the widely-read industry publication Orthopedics This Week for outstanding innovations in the field, for its Fibrin-PTH (KUR-113) technology, which delivers targeted and controlled bone formation. The prestigious...
News 06.11.2020 Schlieren, Switzerland – November 6, 2020 – Memo Therapeutics AG, an innovator in the field of antibody discovery and immune repertoire analysis, announced today that the company has raised CHF 14 million in Series B financing. The round was led by Swisscanto Invest by Zürcher Kantonalbank and included BERNINA BioInvest,...
News 29.10.2020 Zurich-Schlieren, Switzerland, October 29, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending September30, 2020. “Responding to the global COVID-19 pandemic requires an unprecedented effort on...
News 28.10.2020 Zurich-Schlieren, Switzerland, October 28, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and Novartis (SIX: NOVN) today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize...
News 20.10.2020 Schlieren (Zurich), Switzerland, October 20, 2020 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the final number of shares placed and gross proceeds raised in the capital increase first announced on October 5, 2020, in which a total of 10,341,432 newly registered shares of Kuros with a nominal value...